-
-
-
-
-
-
-
BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive'
-
-
-
-
-
-
-
Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Raised to $22 at Baird
-
-
-
-
-
-
-
Sarepta reports $1.86 billion in 2025 product revenue
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Raised to $20 at Bernstein SocGen Group
-
-
-
-
-
-
-
Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform
-
413,523 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

